[Toxicity in the current treatment of pulmonary tuberculosis in children].
Possible toxic side-effects of antituberculous chemotherapy are studied in 718 children affected with pulmonary tuberculosis. 26 (3.62%) presented adverse side-effects and one drug had to be changed in 8 (1.11%). Treatment had to be stopped in one (0.13%) due to toxicity. Liver toxicity was specially studied, showing that younger age is a risk factor (p less than 1 X 10(-10). In 44 cases (16.54%) transient increases of no more than triple of maximum normal value, were found in SGOT and/or SGPT. Toxicity observed in controlled clinical studies and guides for treatment are exposed.
D000293:Adolescent; D000995:Antitubercular Agents / Q000009:adverse effects*; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002648:Child; D002675:Child, Preschool; D003875:Drug Eruptions / Q000209:etiology; D004359:Drug Therapy, Combination; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007538:Isoniazid / Q000009:adverse effects; D009325:Nausea / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D012293:Rifampin / Q000009:adverse effects; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin
Toxicidad en el tratamiento actual de la tuberculosis pulmonar del niño.